IL323596A - HER2 inhibitor dosing schedule - Google Patents

HER2 inhibitor dosing schedule

Info

Publication number
IL323596A
IL323596A IL323596A IL32359625A IL323596A IL 323596 A IL323596 A IL 323596A IL 323596 A IL323596 A IL 323596A IL 32359625 A IL32359625 A IL 32359625A IL 323596 A IL323596 A IL 323596A
Authority
IL
Israel
Prior art keywords
compound
cancer
administered
daily dose
dose
Prior art date
Application number
IL323596A
Other languages
English (en)
Hebrew (he)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IL323596A publication Critical patent/IL323596A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL323596A 2023-03-29 2025-09-28 HER2 inhibitor dosing schedule IL323596A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP23382299 2023-03-29
EP23383067 2023-10-19
EP23383302 2023-12-15
EP24382331 2024-03-27
PCT/EP2024/058464 WO2024200637A2 (en) 2023-03-29 2024-03-28 Dosing schedule of a her2 inhibitor

Publications (1)

Publication Number Publication Date
IL323596A true IL323596A (en) 2025-11-01

Family

ID=90719285

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323596A IL323596A (en) 2023-03-29 2025-09-28 HER2 inhibitor dosing schedule

Country Status (8)

Country Link
EP (1) EP4687907A2 (es)
KR (1) KR20260004349A (es)
CN (1) CN121263188A (es)
AU (1) AU2024247020A1 (es)
CL (1) CL2025002930A1 (es)
IL (1) IL323596A (es)
MX (1) MX2025011417A (es)
WO (1) WO2024200637A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250228858A1 (en) * 2023-12-20 2025-07-17 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
WO2009123894A2 (en) 2008-04-02 2009-10-08 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors

Also Published As

Publication number Publication date
KR20260004349A (ko) 2026-01-08
WO2024200637A3 (en) 2024-12-05
CL2025002930A1 (es) 2026-01-16
AU2024247020A1 (en) 2025-10-30
CN121263188A (zh) 2026-01-02
WO2024200637A2 (en) 2024-10-03
EP4687907A2 (en) 2026-02-11
MX2025011417A (es) 2025-11-03

Similar Documents

Publication Publication Date Title
JP6661734B2 (ja) 線維芽増殖因子受容体２に対するモノクローナル抗体
KR102868124B1 (ko) 암에 대한 치료 및 진단 방법
CN103533960B (zh) c-KIT抗体及其用途
CN110882385B (zh) 抗pd-1抗体在治疗肿瘤中的用途
KR20220133243A (ko) 항 tigit 길항제 항체를 이용한 암의 치료 방법
KR20180008449A (ko) 암에 대한 치료 및 진단 방법
JP2022058699A (ja) 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体
TW202000702A (zh) 用於抗ｔｉｇｉｔ拮抗劑抗體及抗ｐｄ－ｌ１拮抗劑抗體治療之投藥
KR20190072528A (ko) 암에 대한 치료 및 진단 방법
KR20210124535A (ko) 암에 대한 치료 및 진단 방법
JP2010534469A (ja) Ｋｄｒ指向性標的化結合物質およびその使用
IL323596A (en) HER2 inhibitor dosing schedule
EP3957326A1 (en) Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors
AU2009244091B2 (en) IGF-II/GF-IIE binding proteins
KR20210063330A (ko) 방광암에 대한 치료 및 진단 방법
TW202126690A (zh) 用抗ｔｉｇｉｔ和抗ｐｄ－ｌ１拮抗劑抗體給藥治療
US20250228858A1 (en) Anti-cancer combination therapy
US20230250195A1 (en) Methods for Reducing Infusion-Related Reactions in Patients Treated with EGFR/Met Bispecific Antibodies
US20230250182A1 (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
JP2026513532A (ja) Ｈｅｒ２阻害剤の投薬スケジュール
US20260034134A1 (en) Treatment of cancer with metastases in the central nervous system
JP2023523450A (ja) 非小細胞肺がん免疫療法のための方法及び組成物
WO2020033283A1 (en) Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc
CN111886257A (zh) 用于疾病和病症治疗和预防的抗-肾酶抗体
WO2025051693A1 (en) Cancer treatment with a her2 inhibitor and a cyp3a and/or p-gp modulator